The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...
Nucala (mepolizumab) and Dupixent (dupilumab) are brand-name subcutaneous injections. They’re both prescribed for asthma and chronic rhinosinusitis with nasal polyps. Each drug may also be ...
Pharmaceutical Technology on MSN9d
EMA to review GSK’s Nucala for COPD treatment expansionThe EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.
Nucala isn’t known to interact with drugs, supplements, or alcohol. However, Nucala may cause certain vaccines to be less effective. Talk with your doctor to help avoid potentially harmful ...
The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
El biológico, ya aprobado para el asma grave, podría convertirse en el primer tratamiento mensual autorizado para esta forma ...
GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or ...
GSK ha anunciado hoy que la Agencia Europea de Medicamentos (EMA) ha aceptado revisar su solicitud de ampliar el uso de ...
March 24 (Reuters) - The European Medicines Agency will review GSK's (GSK.L), opens new tab request to approve its asthma drug Nucala as an additional treatment for chronic obstructive pulmonary ...
Nucala (mepolizumab) is a prescription injection used to treat a type of asthma and other inflammatory conditions. Nucala isn’t known to interact with other drugs, alcohol, or supplements.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback